HER-2/neu and topoisomerase IIalpha in breast cancer (Q35130680)

6 August 2017

1 reference

title

HER-2/neu and topoisomerase IIalpha in breast cancer (English)

1 reference

6 August 2017

Tero A H Järvinen

1

1 reference

6 August 2017

Edison T Liu

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

Breast Cancer Research and Treatment

6 August 2017

published in

1 reference

6 August 2017

volume

78

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

299-311

1 reference

Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

Amplification of growth regulatory genes in intraductal breast cancer is associated with higher nuclear grade but not with the progression to invasiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

Differential expression of the topoisomerase II alpha and beta genes in human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

21 January 2018

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

Physiological regulation of eukaryotic topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Effects of HER-2/neu on chemosensitivity of tumor cells

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Molecular targets for breast cancer therapy and prevention

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

HER2/neu: mechanisms of dimerization/oligomerization

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Improving the efficacy of antibody-based cancer therapies

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect.

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

The 1998 St. Gallen's Consensus Conference: an assessment

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Using HER2 to choose chemotherapy in breast cancer: is it ready for the clinic?

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Concomitant gastrin and ERBB2 gene amplifications at 17q12-q21 in the intestinal type of gastric cancer

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Amplification and expression of genes from the 17q11 approximately q12 amplicon in breast cancer cells

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Amplification of HSD17B1 and ERBB2 in primary breast cancer

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Comparison of Topoisomerase-IIα Gene Status between Primary Breast Cancer and Corresponding Distant Metastatic Sites

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

https://api.crossref.org/works/10.1023/A:1023077507295

1 reference

7 January 2021

Culprit and victim -- DNA topoisomerase II.

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

DNA topoisomerase IIbeta and neural development

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Predictive factors for response to chemotherapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

The basic biology of HER2.

1 reference

https://api.crossref.org/works/10.1023/A:1023077507295

7 January 2021

Identifiers

DOI

10.1023/A:1023077507295

1 reference

Dimensions Publication ID

6 August 2017

1003972047

0 references

1 reference